You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

stage III marginal zone lymphoma

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Splenic Marginal Zone Lymphoma Trial in Worldwide (Rituximab, Zanubrutinib)

Not yet recruiting
  • Splenic Marginal Zone Lymphoma
  • Aarhus, Denmark
  • +4 more
Feb 17, 2023

Lymphoma Trial in Milan (clarithromycin, oral, high dose)

Completed
  • Lymphoma
  • clarithromycin, oral, high dose
  • Milan, Italy
    Dpt of OncoHematology - Fondazione Centro San Raffaele del Monte
Aug 10, 2022

Marginal Zone Lymphoma Trial in Germany (Obinutuzumab)

Active, not recruiting
  • Marginal Zone Lymphoma
  • Bochum, Germany
  • +15 more
Nov 4, 2022

Marginal Zone Lymphoma Trial in Miami (Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg)

Recruiting
  • Marginal Zone Lymphoma
  • Loncastuximab tesirine 150 µg/Kg
  • Loncastuximab tesirine 75µg/Kg
  • Miami, Florida
    University of Miami
Jul 12, 2022

Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission Trial in Seattle (drug,

Terminated
Has Results
  • Acute Biphenotypic Leukemia
  • +29 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 4, 2023

Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma Trial in Worldwide (Ibrutinib, Rituximab)

Recruiting
  • Marginal Zone Lymphoma
  • +2 more
  • Yvoir, Belgium
  • +36 more
Nov 4, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma Trial in New Haven, New Brunswick, Providence (Mosunetuzumab,

Recruiting
  • Follicular Lymphoma
  • +2 more
  • New Haven, Connecticut
  • +2 more
Jul 14, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)

Withdrawn
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • (no location specified)
Jul 14, 2022

Follicular Lymphoma (Gastric or Duodenal), Marginal Zone Lymphoma (Gastric or Duodenal) Trial in Münster (Radiation Therapy)

Recruiting
  • Follicular Lymphoma (Gastric or Duodenal)
  • Marginal Zone Lymphoma (Gastric or Duodenal)
  • Radiation Therapy
  • Münster, North Rhine-Westphalia, Germany
    Department of Radiation Oncology
Dec 1, 2021

Marginal Zone Lymphoma and Its Prognostic Role

Recruiting
  • Marginal Zone Lymphoma
    • Dijon, France
    • +22 more
    Jan 17, 2023

    Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Extranodal Marginal

    Completed
    Has Results
    • Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
    • +2 more
    • Radiation Therapy
    • Houston, Texas
      M D Anderson Cancer Center
    Feb 25, 2022

    Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

    Active, not recruiting
    • Adult Grade III Lymphomatoid Granulomatosis
    • +23 more
    • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    Jan 4, 2023

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

    Suspended
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +7 more
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Jan 20, 2023

    Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

    Not yet recruiting
    • Relapsed Non-Hodgkin Lymphoma
    • +6 more
    • (no location specified)
    Apr 12, 2023

    Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

    Withdrawn
    • Recurrent Follicular Lymphoma
    • +8 more
    • (no location specified)
    Jun 2, 2022

    Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

    Completed
    • Grade 3a Follicular Lymphoma
    • +9 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 31, 2023

    Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

    Withdrawn
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • (no location specified)
    Jun 28, 2023

    Primary Ocular Adnexal MALT Lymphoma Trial (Rituximab, Involved Site Radiation Therapy)

    Not yet recruiting
    • Primary Ocular Adnexal MALT Lymphoma
    • (no location specified)
    Sep 26, 2023

    Revlimid® Capsules General Drug Use-results Surveillance

    Recruiting
    • Lymphoma Nonhodgkin
      • Japan, Japan
        Local Institution
      Jun 22, 2022

      B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

      Recruiting
      • B-cell Lymphoma
      • +5 more
      • Louisville, Kentucky
        Norton Cancer Institute
      Jan 24, 2023

      Marginal Zone Lymphoma Trial in Austria, Germany (Copanlisib, Rituximab)

      Recruiting
      • Marginal Zone Lymphoma
      • Wien, Austria
      • +19 more
      Mar 14, 2022

      Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in Miami (Acalabrutinib,

      Terminated
      Has Results
      • Diffuse Large B Cell Lymphoma
      • +3 more
      • Miami, Florida
        University of Miami
      Aug 23, 2022

      MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,

      Completed
      • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
      • +8 more
      • PI3K inhibitor BKM120
      • +3 more
      • Atlanta, Georgia
      • +1 more
      Jun 27, 2022

      Follicular Lymphoma and Marginal Zone Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide,

      Recruiting
      • Follicular Lymphoma and Marginal Zone Lymphoma
      • Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
      • lenalinomide
      • Beijing, China
        Chinese Academy of Medical Sciences and Peking Union Medical Col
      Feb 13, 2022